Overview

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.

Status:
Withdrawn

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This is an open-label, parallel-group, nonrandomized, multi-centre, phase-IV, single dose trial in 8 HIV-seronegative subjects with severe hepatic impairment and 8 matched controls to assess the pharmacokinetics of a single dose of 50mg of dolutegravir in subjects with severe hepatic impairment.

Phase:

Phase 4

Details

Lead Sponsor:

Radboud University

Collaborators:

Erasmus Medical Center
Leiden University Medical Center
University Medical Center Groningen

Treatments:

Dolutegravir